Biopharma News

Aug 01, 2018
By BioPharm International Editors
The companies will work together to develop novel gamma delta T-cell receptor therapies in various cancers.
Aug 01, 2018
By BioPharm International Editors
GlaxoSmithKline and 23andMe, a personal genomics and biotechnology company, will partner to research and develop new drugs using human genetics.
Jul 28, 2018
By BioPharm International Editors
Novartis is set to partner with MorphoSys and Galapagos in a deal worth up to $1.1 billion to develop and commercialize their joint investigational, fully human, IgG1 monoclonal antibody (mAb) directed against the target IL-17C.
Jul 27, 2018
By BioPharm International Editors
Pfizer will invest nearly half a billion dollars to build a sterile injectable facility in Michigan.
Jul 26, 2018
By BioPharm International Editors
The acquisition would combine Sangamo’s ex vivo gene-editing capabilities with TxCell's regulatory T-cell (Treg) expertise to create chimeric antigen receptor (CAR)-Treg therapies.
Jul 19, 2018
In launching FDA’s Biosimilar Action Plan, Gottlieb takes innovator companies to task for delaying competitive biosimilar products.
Jul 19, 2018
By BioPharm International Editors
The company has run into a snag in producing Kymriah for the diffuse large B-cell lymphoma patient population, the second indication for which the therapy was recently approved by FDA.
Jul 18, 2018
By BioPharm International Editors
CELLforCURE will produce cancer CAR-T treatments for Novartis at a manufacturing facility in Les Ulis (Essonne), France.
Jul 18, 2018
By BioPharm International Editors
AbbVie will grant Mylan license to launch a biosimilar to AbbVie’s Humira.
Jul 17, 2018
By BioPharm International Editors
Moderna’s new manufacturing plant in Norwood, MA gives the company capacity for preclinical and Phase I and II clinical manufacturing for its mRNA development candidates, including personalized cancer vaccines.
native1_300x100
lorem ipsum